Blueprint Medicines initiated at Leerink
Blueprint Medicines initiated with an Outperform at Leerink. Leerink analyst Andrew Berens started Blueprint Medicines with an Outperform rating and $105 price target. https://thefly.com/landingPageNews.php?id=2794745
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.